| Study Period | 2021 - 2032 |
| Market Size in 2025 | USD 86.5 Million |
| Market Size in 2026 | USD 93.9 Million |
| Market Size by 2032 | USD 161.9 Million |
| Projected CAGR | 9.4% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| Market Structure | Semi-Consolidated |
Explore the market potential with our data-driven report
The leukapheresis market size was USD 86.5 million for 2025, and it will grow by 9.4% during 2026–2032, to reach USD 161.9 million by 2032.
The rising global burden of hematologic malignancies and autoimmune disorders is sustaining this growth. Expanding adoption of chimeric antigen receptor (CAR) T-cell therapies and growing reliance on leukapheresis-derived leukopaks across stem cell transplantation and immuno-oncology research are reinforcing this trajectory. As biopharmaceutical companies and specialized cell-therapy manufacturers scale commercial-grade collection capacity, leukapheresis has evolved from a niche transfusion-medicine procedure into a foundational upstream step within the broader cell and gene therapy value chain.
Demand validation is evident in the scale of underlying disease burden and regulatory momentum. The National Cancer Institute estimates that approximately 62,770 new leukemia cases were diagnosed in the United States in 2024. This disease burden is sustaining consistent clinical demand for leukapheresis-based collection procedures. The U.S. Food and Drug Administration continues to expand its roster of approved CAR T-cell therapies requiring patient-specific leukapheresis as a mandatory first manufacturing step, including its 2024 approvals of lisocabtagene maraleucel (Breyanzi) for follicular lymphoma and mantle cell lymphoma. These regulatory milestones are accelerating capital investment in automated, closed-system apheresis platforms and single-use disposable kits engineered to improve cell yield and reduce contamination risk.
The market is undergoing a clear shift away from manual, discontinuous-flow apheresis toward automated, closed-system continuous-flow platforms that improve cell yield, reduce contamination risk, shorten donor chair time, and enhance workflow efficiency. These technological advancements are enabling greater standardization and reducing procedural variability. This standardization supports the consistent collection of high-quality cellular products required for stem cell transplantation, CAR T-cell therapy, and other cell and gene therapy applications. As healthcare providers and biopharmaceutical companies increasingly prioritize operational efficiency and product quality, the adoption of automated leukapheresis systems continues to accelerate.
Peer-reviewed analysis of 1,580 CAR-T clinical trials registered on ClinicalTrials.gov as of April 2024 shows that 1,139 trials were initiated between January 2020 and April 2024 alone. This trial volume highlights the rapid expansion of CAR-T clinical development and the growing demand for standardized leukapheresis collection procedures across clinical trial sites. As trial networks expand geographically, sponsors increasingly favor apheresis platforms with integrated monitoring and automated quality controls. This preference is driving investment in next-generation leukapheresis technologies and supporting overall market growth.
The expanding adoption of chimeric antigen receptor (CAR) T-cell therapies is a major driver for the leukapheresis market, as leukapheresis is the mandatory first step in the manufacturing of autologous CAR-T products. During the leukapheresis procedure, a patient's T cells are collected before being genetically modified and expanded for therapeutic use. Every increase in approved CAR-T indications and treatment volumes is translating into higher demand for leukapheresis procedures, advanced apheresis systems, and single-use disposable collection kits. Growing clinical adoption of cell and gene therapies, alongside the expansion of cellular therapy programs and manufacturing capacity, is reinforcing demand for leukapheresis technologies throughout the forecast period. The sustained burden of hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, continues to support the long-term need for leukapheresis in both therapeutic applications and cell therapy manufacturing.
The National Cancer Institute's SEER Program reports that age-adjusted rates for new leukemia cases have remained stable over 2014–2023. This stability reflects the continued clinical need for leukemia diagnosis and treatment. Regulatory agencies continue to expand approvals for CAR-T therapies across hematologic malignancies, increasing the number of eligible patients and reinforcing demand for leukapheresis-based cell collection. For instance, in January 2023, Charles River Laboratories International launched its CliniPrime Fresh Leukopak offering, providing GMP-compliant cellular starting materials to support clinical and commercial cell and gene therapy manufacturing.
Despite underlying demand, high upfront capital costs for automated apheresis systems and continued reimbursement uncertainty at the hospital level are constraining broader adoption among smaller transplant centers and blood banks in cost-sensitive healthcare systems. Closed-system platforms and GMP-compliant collection suites require capital outlay that smaller institutions often cannot justify without assured procedure volumes. Maintenance costs, staff training requirements, and compliance with quality and regulatory standards further increase the total cost of ownership for leukapheresis systems. Limited capital budgets and uncertain reimbursement discourage investment in advanced leukapheresis infrastructure. This underinvestment is restricting the expansion of collection capacity and slowing the adoption of automated apheresis technologies across healthcare facilities.
Reimbursement policies for advanced cell and gene therapies continue to vary across healthcare systems. This variability is creating financial uncertainty for hospitals investing in leukapheresis infrastructure and associated collection services. High treatment costs and evolving reimbursement frameworks make it challenging for smaller healthcare providers and blood centers to recover investments in specialized equipment and facilities. This challenge is limiting the pace of capacity expansion despite growing clinical demand for leukapheresis procedures.
While first-generation CAR-T relies on autologous, patient-specific collection, the emerging shift toward allogeneic, donor-derived off-the-shelf cell therapies is opening a structurally different growth pathway centered on large-scale donor apheresis rather than single-patient collection events. This shift could expand collection volumes per donor session, as one qualified donor's leukapheresis output can supply multiple therapeutic doses instead of a single patient course.
Allogene Therapeutics has indicated that its off-the-shelf allogeneic CAR-T platform is designed with a target manufacturing scalability of approximately 30,000 to more than 60,000 doses annually, illustrating the potential scale of donor-based collection models. As allogeneic cell therapy programs continue to advance in clinical development, blood centers, contract manufacturers, and leukapheresis service providers are well positioned to support increasing demand for donor-derived cell collection.
The disposables category holds the larger market share of 75% in 2025, driven by the recurrent, single-use nature of collection kits, tubing sets, needles, anticoagulant solutions, and filters consumed with every leukapheresis procedure, while stringent sterility and patient-safety requirements necessitate new disposable components for every collection session, effectively converting each procedure into a recurring purchase. Increasing leukapheresis procedure volumes associated with stem cell transplantation, CAR-T therapy manufacturing, and clinical research continue to reinforce the segment's structural lead over capital equipment. According to the Association for the Advancement of Blood & Biotherapies (AABB), the 35th edition of the Standards for Blood Banks and Transfusion Services became effective on April, 2026. This edition maintains mandatory quality and safety requirements for blood collection and transfusion services, reinforcing the continued use of validated sterile collection systems across accredited facilities.
The devices category will have the higher CAGR of approximately 9.7%, driven by increasing adoption of automated continuous-flow leukapheresis systems that improve collection efficiency, enhance cell yield, reduce procedure time, and minimize donor reactions. Expanding investments in cell and gene therapy manufacturing, growing establishment of in-house collection facilities by biopharmaceutical companies, and continuous technological advancements in apheresis platforms are accelerating replacement of legacy equipment and supporting robust growth in the devices segment.
The offerings analyzed in this report are:
The therapeutic category holds the larger market share in 2025. This is attributed to the robust global network of companies offering leukapheresis equipment and disposables for therapy. Moreover, hospitals are rapidly acquiring leukapheresis equipment to treat patients for a range of blood-borne disorders. The increasing number of hematopoietic stem cell transplantation procedures and the expanding adoption of therapeutic apheresis for hematologic and autoimmune disorders are further supporting the dominance of this category.
The research category will have the higher CAGR of approximately 9.9%, due to the rising usage of leukapheresis products for the creation of cell-based immunotherapies, surging need for leukopaks in scientific research, and escalating adoption of leukapheresis-derived primary cells in pharmaceutical research and development. Growing translational research activities and expanding cell therapy pipelines are further accelerating demand for research-grade leukapheresis collections.
The applications analyzed in this report are:
The hospitals and transfusion centers category holds the largest market share of 45% in 2025, reflecting their position as the primary point of care for both emergency therapeutic apheresis procedures and CAR-T patient collection appointments, supported by their existing transfusion medicine infrastructure and clinical staff trained in apheresis protocols. This end-user category benefits from direct integration with hospital blood banks and transplant programs, enabling same-facility coordination between collection, processing, and reinfusion that smaller or specialized providers cannot easily replicate.
The pharmaceutical and biotechnology companies category will have the highest CAGR, driven by the accelerating build-out of in-house and outsourced leukapheresis collection capacity, which is feeding commercial CAR-T manufacturing pipelines and supporting growing clinical trial networks for both autologous and allogeneic cell therapy candidates. The Alliance for Regenerative Medicine reported that global cell and gene therapy investment reached USD 15.2 billion in 2024, representing a 30% year-over-year increase. This investment growth is directly supporting expanding collection capacity and leukapheresis demand among pharmaceutical and biotechnology companies.
The end users analyzed in this report are:
Drive strategic growth with comprehensive market analysis
North America holds the largest market share of 40% in 2025. This is due to the substantial research and development activities in the pharmaceutical and biotechnology sectors. This region also has a stronghold due to the presence of a large number of industry players and healthcare providers, the high count of ongoing CAR T-cell therapy clinical trials. Additionally, the region's rapid adoption of new technologies and the rising prevalence of chronic diseases support the expansion of the regional industry.
The region also benefits from a well-established network of accredited apheresis and cell-collection centers, advanced CAR T-cell manufacturing infrastructure, and favorable reimbursement frameworks that facilitate the adoption of leukapheresis procedures in clinical and research settings. According to the U.S. Health Resources and Services Administration (HRSA), the C.W. Bill Young Cell Transplantation Program (CWBYCTP) facilitated over 8,400 unrelated blood stem cell transplants during Fiscal Year 2025, including over 7,200 for patients in the United States, highlighting the robust stem cell transplantation ecosystem that supports sustained demand for leukapheresis-based cell collection procedures.
The U.S. accounted for the largest share and is the fastest-growing country market within North America, driven by a dense network of FACT-accredited cellular therapy programs. Nearly all major leukapheresis device and disposable manufacturers maintain commercial operations in the country, and a well-established clinical trial ecosystem supports cell and gene therapy development within its borders. The Foundation for Accreditation of Cellular Therapy (FACT) maintains a directory of accredited cellular therapy and apheresis collection programs in the United States, with participating centers undergoing reaccreditation every three years to maintain quality and safety standards.
Asia-Pacific will have the highest CAGR of approximately 10.3%, mainly on account of the improving healthcare infrastructure, increasing prevalence of leukemia in the region, rising per capita income, and growing geriatric population. Additionally, the market is growing due to the government programs to raise awareness and the technological improvements in hematology. Moreover, the expansion in the network of cancer hospitals and blood donation and processing centers in this region contributes to the market's growth.
The region is witnessing increasing investment in cell and gene therapy manufacturing. Accredited apheresis and stem cell collection facilities are expanding, and clinical research activity is rising across China, Japan, South Korea, and India. Favorable government initiatives to strengthen blood transfusion services and growing adoption of advanced apheresis technologies are accelerating market expansion. In India, the National Blood Transfusion Council (NBTC), operating under the National AIDS Control Organisation (NACO), coordinates blood transfusion services through State Blood Transfusion Councils across all states. This coordination is strengthening the country's blood collection and transfusion infrastructure and supporting wider adoption of apheresis-based procedures.
China held the largest share within the Asia-Pacific leukapheresis market, driven by the aggressive domestic approval of cell therapies. Rapid expansion of hospital and research infrastructure and government-backed investment in biomanufacturing under the Healthy China 2030 initiative are reinforcing this trajectory. Domestic CAR-T developers have progressively localized cell therapy manufacturing and expanded hospital-based collection centers. This localization is strengthening the country's leukapheresis ecosystem.
China's National Medical Products Administration (NMPA) approved zevorcabtagene autoleucel, a BCMA-targeted CAR T-cell therapy, in March 2024 for relapsed or refractory multiple myeloma. This approval extends the roster of domestically approved therapies requiring leukapheresis-based cell collection.
These regions and countries are analysed:
The market exhibits a semi-consolidated structure, with a small group of established medical device and disposables manufacturers accounting for a share of collective revenue, while specialized cell-collection and research-services providers compete in adjacent niches. High barriers to entry support this market structure. Regulatory clearance pathways for closed-system apheresis devices are lengthy and capital-intensive, and manufacturing sterile, cell-therapy-grade disposables requires specialized production infrastructure. Longstanding clinical relationships with hospitals and blood centers create switching costs. Leading companies strengthen their positions through extensive installed bases, advanced continuous-flow collection systems, broad transfusion-medicine portfolios, and established collaborations with hospitals and cell therapy manufacturers, limiting the ability of new entrants to rapidly gain market share.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages